Willems J L, Willems R J, Willems G M, Arnold A E, Van de Werf F, Verstraete M
Division of Medical Informatics, University of Leuven, Belgium.
Circulation. 1990 Oct;82(4):1147-58. doi: 10.1161/01.cir.82.4.1147.
To determine the ability of initial ST segment elevation and depression to predict infarct size limitation by thrombolytic therapy, data were analyzed in 721 patients with acute myocardial infarction who were admitted to a randomized, placebo-controlled study of intravenous recombinant tissue-type plasminogen activator. Patients with QRS duration of 120 msec or more or with previous history of myocardial infarction were excluded, leaving 322 in the treatment and 333 in the placebo group. Cumulative 72-hour release of alpha-hydroxybutyrate dehydrogenase and global ejection fraction as well as left ventricular wall motion derived from angiography were used as independent measures of infarct size. Electrocardiograms obtained at admission, 6 hours after start of therapy, and before discharge were analyzed. All ST measurements were made by hand at the J point and 60 msec after the J point. Patients with high ST segment elevation at admission (i.e., sum of ST elevation at 60 msec after the J point was 20 mm or more) had significantly larger infarction and higher hospital mortality when compared with those with lower (less than 20 mm) ST elevation. Reciprocal ST segment depression also showed a linear relation with infarct size and mortality, independent from ST elevation, both in anterior and inferior myocardial infarction. The sum of deviations measured at the J point and 60 msec after the J point differed significantly, especially in anterior myocardial infarction at admission (mean, 16 +/- 9 versus 23 +/- 11 mm). The prognostic value of one measurement was not, however, superior over the other. Treatment with recombinant tissue-type plasminogen activator was most effective in those with large ST deviations at admission, but patients with anterior infarction and smaller ST shifts also appeared to benefit from therapy. Results in individual patients were variable, and the overall correlation of initial ST shifts with enzymatic infarct size was rather low. In conclusion, the present study shows that the magnitude of initial ST elevation and also of reciprocal ST depression in the admission electrocardiogram is valuable for the management and assessment of thrombolytic therapy in patients with acute myocardial infarction.
为了确定初始ST段抬高和压低预测溶栓治疗梗死面积限制的能力,我们分析了721例急性心肌梗死患者的数据,这些患者被纳入一项静脉注射重组组织型纤溶酶原激活剂的随机、安慰剂对照研究。排除QRS时限达120毫秒或更长或有心肌梗死病史的患者,治疗组剩下322例,安慰剂组剩下333例。α-羟丁酸脱氢酶的72小时累积释放量、整体射血分数以及血管造影得出的左心室壁运动情况被用作梗死面积的独立测量指标。分析了入院时、治疗开始后6小时及出院前获得的心电图。所有ST段测量均在J点及J点后60毫秒处手工进行。入院时ST段抬高程度高的患者(即J点后60毫秒处ST段抬高总和为20毫米或更高)与ST段抬高程度低(小于20毫米)的患者相比,梗死面积显著更大,医院死亡率更高。在前壁和下壁心肌梗死中,对应ST段压低与梗死面积和死亡率也呈线性关系,独立于ST段抬高。在J点及J点后60毫秒处测量的偏差总和差异显著,尤其是入院时的前壁心肌梗死(平均值分别为16±9毫米和23±11毫米)。然而,一种测量方法的预后价值并不优于另一种。重组组织型纤溶酶原激活剂治疗对入院时ST段偏差大的患者最有效,但前壁梗死且ST段移位较小的患者似乎也从治疗中获益。个体患者的结果存在差异,初始ST段移位与酶学梗死面积的总体相关性相当低。总之,本研究表明,入院心电图中初始ST段抬高以及对应ST段压低的程度对于急性心肌梗死患者溶栓治疗的管理和评估具有重要价值。